BioCryst Crushes It on Rare Immune Disorder Drug Trial

BioCryst’s treatment, BCX4161, is a novel, selective inhibitor of plasma kallikrein in development for prevention of attacks in patients with HAE. The drug suppresses the body’s production of bradykinin, which is a cause of acute swelling attacks in HAE sufferers.

BioCryst has been on something of a tear over the past 12 months. The share price is up more than 460%, and the stock reached its 52-week high shortly after the announcement in early March of a successful Phase 1 clinical trial of BCX4161.

Shares were up more than 11%, after rising as much as 20% earlier Tuesday morning. The stock was trading at $10.07 a half-hour after the open. The 52-week range is $1.42 to $13.33.

ALSO READ: Why You Buy Big Pharma If the Market Crashes